Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06817024 in Healthy Subjects, CRSwNP, and Atopic Dermatitis
NCT02743871Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2016
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06817024 in chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD) (13 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With All-causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants With Treatment-Related TEAEs and SAEs and 5 more. Started Apr 2016; status: completed.
02
Drugs
PF-06817024
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02743871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743871.